Determining blood clotting reference values for pregnant women
Thrombophilia Assessment and Pregnancy: Determination of Reference Values for dRVVT in Pregnant Women
This study is trying to find out the normal blood clotting levels for pregnant women to help manage their risk of blood clots during pregnancy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | Female |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 1 site (Lyon) |
| Trial ID | NCT06133621 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish reference values for the diluted Russell's viper venom time (dRVVT) specifically in pregnant women. It focuses on understanding the changes in haemostasis during pregnancy, which can lead to a hypercoagulable state and increase the risk of thromboembolic events. The study will involve monitoring pregnant women with normal pregnancies and those with elevated dRVVT ratios to assess the implications for vascular diseases of pregnancy. The findings could help improve the management of pregnant women at risk for complications related to blood clotting.
Who should consider this trial
Good fit: Ideal candidates include pregnant women with normal pregnancies and those with increased dRVVT ratios being monitored for vascular diseases of pregnancy.
Not a fit: Patients with a history of thromboembolic disease, autoimmune disease, or vascular diseases of pregnancy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding and management of thromboembolic risks in pregnant women, potentially improving maternal and fetal outcomes.
How similar studies have performed: While this approach is focused on a specific population, similar studies have shown the importance of monitoring coagulation parameters in pregnancy, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Control group : * patients with normal pregnancies at the HCL. * Affiliation to a social security regime Case group : * Patients followed at the HCL who had an increased dRVVT ratio during pregnancy, investigated as part of the development of VDP during pregnancy. * Affiliation to a social security regime Exclusion Criteria: * History of thromboembolic disease * History of autoimmune disease * History of VDP
Where this trial is running
Lyon
- Dr Céline BAZIN — Lyon, France (Recruiting)
Study contacts
- Principal investigator: Céline DR BAZIN, DR — Laboratoire d'hémostase CBPE HCL
- Study coordinator: Céline DR BAZIN, DR-
- Email: celine.bazin01@chu-lyon.fr
- Phone: 04 72 35 72 47
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.